MedPath

AC/DC Study: Acidification Test in Patients With Chronic Kidney Disease and Healthy Controls

Not Applicable
Completed
Conditions
Chronic Kidney Disease stage4
Interventions
Diagnostic Test: Urinary acidification test
Registration Number
NCT03293446
Lead Sponsor
Erasmus Medical Center
Brief Summary

In this study the effect of an acute acid load on the intrarenal renin angiotensin-system is evaluated in patients with chronic kidney disease and healthy controls

Detailed Description

Metabolic acidosis is one of the metabolic complications of chronic kidney disease (CKD). Correction of metabolic acidosis in CKD has been shown to prevent further loss of kidney function over time. Currently, a clinical trial (the BIC-study, MEC-2013-332) is conducted in which patients with CKD and metabolic acidosis receive sodium bicarbonate, sodium chloride, or no treatment (time control) to address the hypothesis that the beneficial effects of acidosis correction are mediated through inhibition of the intrarenal renin-angiotensin system (RAS). It is unknown, however, if and how acute changes in acid-base status affect the intrarenal RAS during CKD. In the present study it is hypothesized that an acute acid load increases the activity of the intrarenal RAS, and that this response is exaggerated in patients with CKD compared with healthy controls.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
29
Inclusion Criteria

Not provided

Exclusion Criteria
  • CKD patients
  • Plasma bicarbonate level < 20.0 mmol/l
  • Serum potassium >5.5 mmol/l
  • Sodium bicarbonate use in the month preceding the test
  • Heart failure (NYHA III or IV)
  • Liver cirrhosis (Child Pugh B or C)
  • Blood pressure >140/90 mmHg despite the use of 3 different anti-hypertensive drugs
  • Kidney transplantation
  • Use of calcineurin inhibitors (these immunosuppressive drugs affect acid-base balance)
  • Known urea cycle disorder
  • Alcoholism or drug use
  • Pregnancy
  • Current use of antibiotics, NSAIDS or alkalizing drugs (sodium-bicarbonate, citric acid, potassium citrate, acetazolamide)
  • Inability to adhere to the study protocol (due to language barrier or intellectual disability)

Healthy controls:

  • eGFR < 90 ml/min/1.73 m2 (calculated using the CKD-EPI equation)
  • Plasma bicarbonate < 20 mmol/l
  • History of, or drugs for, diabetes mellitus
  • History of chronic diarrheal disease
  • Ileostomy/colostomy
  • Known urea cycle disorder
  • Alcoholism or drug use
  • Pregnancy
  • Current use of antibiotics, antihypertensive drugs, NSAIDS or alkalizing drugs (sodium-bicarbonate, citric acid, potassium citrate, acetazolamide)
  • Inability to adhere to the study protocol (due to language barrier or intellectual disability)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Patients with chronic kidney diseaseUrinary acidification test-
Healthy controlsUrinary acidification test-
Primary Outcome Measures
NameTimeMethod
Urinary reninup to 6 hours
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Erasmus MC

🇳🇱

Rotterdam, Zuid-Holland, Netherlands

© Copyright 2025. All Rights Reserved by MedPath